Company: GNMSF
Filing Date: 2025-02-12
Form Type: 20-F
Source: 0001558370-25-000846
Chunk: 165

Company: GENMAB A/S
Filing Date: 2025-02-12
Form: 20-F
Item: Item 16K
Chunk 165
---
PART III

ITEM 17 FINANCIAL STATEMENTS

See“ Item 18 - Financial Statements.”

ITEM 18 FINANCIAL STATEMENTS

The financial statements required by this item are incorporated herein by reference to pages 139-182 of our Annual Report 2024.

ITEM 19 EXHIBITS

  Annual Report  
 ─────────────────

The following pages from ourAnnual Report 2024, furnished to the SEC as Exhibit 99.1(a) to Form 6-K, dated February 12, 2025are incorporated by reference into this Form 20-F. The content of websites, scientific articles and other sources referenced on these pages are not incorporated by reference into this Annual Report on Form 20-F.

Page(s) incorporated by reference from our Annual Report 2024

Financial Review - pages 52-60

Consolidated Financial Statements for the Genmab Group - pages 139-182

Table of Contents

Consolidated Statements of Comprehensive Income for the years ended December 31, 2024, 2023 and 2022 - page 140

Consolidated Balance Sheets as of December 31, 2024 and 2023 - page 141

Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023 and 2022 - page 142

Consolidated Statements of Changes in Equity for the years ended December 31, 2024, 2023 and 2022 - page 143

Notes to the Consolidated Financial Statements - pages 144-182

  Exhibits  

Exhibit Index

  Exhibit No.      Description                                                                                                                                                 Method of filing                                                                                                                                
  1.1              English translation of Articles of Association of Genmab A/S, as currently in effect                                                                        Incorporated by reference to the Registrant’s Report furnished to the SEC on Form 6-K onJanuary 29, 2025                                        
  2.3              Description of Securities Registered under Section 12 of the Exchange Act                                                                                   Incorporated by reference to Exhibit 2.3 to the Registrant’s Annual Report on Form 20-F filed with the SEC on March 29, 2021                    
  4.1 †            Agreement with J& J related to DARZALEX - License Agreement, dated as of August 30, 2012, by and between Janssen Biotech, Inc. and Genmab A/S               Incorporated by reference to Exhibit 10